Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Drug Alcohol Depend. 2010 Jan 25;109(1-3):20–29. doi: 10.1016/j.drugalcdep.2009.11.023

Figure 2.

Figure 2

Proportion of participants with methamphetamine (MA) metabolite- free urine drug screens during the two week baseline period (b1, b2) and 12 week medication treatment period (t1–t12) in the total sample, and separately for participants with baseline lower frequency (18 or fewer of the past 30 days) versus higher frequency (more than 18 of the past 30 days) MA use and low CBT attendance (0–2 sessions) versus high CBT attendance (3 or more sessions).